ProCE Banner Activity

ARTISTRY-1: Wk 48 Data After Switch From Complex ART to Bictegravir + Lenacapavir in Virologically Suppressed People With HIV

Conference Coverage
Slideset

Phase II results of ARTISTRY-1 confirm that switch to simplified regimen was effective and safe over 48 weeks. BIC 75 mg + LEN 50 mg (now as a single-tablet regimen) to be evaluated in phase III.

Released: July 26, 2024

Expiration: July 25, 2025

Share

Faculty

Angela Davies

Angela Davies, MD

Assistant Professor of Medicine
UC Davis Cancer Center
Sacramento, CA

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner